Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
Natco Pharma ties up with Gilead on hepatitis C drugs

Natco, a mid-sized player in India's crowded pharmaceutical industry, is the latest generic drugmaker to team up with Gilead on Sovaldi, having previously attempted to block the U.S. firm from getting a patent for the breakthrough drug in India in the hope of producing a cheaper version on its own. In September, Gilead announced similar licensing deals with seven other generic drugmakers.

Published
04 March 2015
From
Reuters
PrEP Access For HIV Prevention In Australia A Step Closer As Gilead Applies To TGA

US pharmaceutical giant Gilead Sciences has begun the application process to have Truvada approved for PrEP in Australia, removing one of the most significant hurdles currently preventing access to the HIV-prevention drug and opening the door to affordable access.

Published
03 March 2015
From
Star Observer
Gilead avoids billions in U.S. taxes on its $1,000-a-pill drug

Gilead Sciences Inc., whose $1,000-a-pill hepatitis C treatment is one of the world's most expensive drugs, is avoiding billions of dollars in U.S. taxes by booking profits overseas.

Published
27 February 2015
From
Chicago Tribune
HIV and LGTB NGOs and other concerned actors across Europe call for futher action on pre-exposure prophylaxis

The European AIDS Treatment Group (EATG), Europe’s network of HIV activists, and  AIDES, a leading French NGO in the fight against AIDS and viral hepatitis, backed by 81 European HIV LGBT civil society organisations and concerned actors, issued an urgent HIV Prevention Manifesto today. We demand that pre-exposure prophylaxis for HIV (PrEP) is made available as soon as possible within the European Union, and that Gilead, the company that makes the PrEP medicine Truvada®, submits an application to the European Medicines Agency (EMA) for a change of indication so that its use to prevent HIV can be approved.

Published
25 February 2015
From
EATG
Merck places children's HIV drug in shared non-profit patent pool

U.S. drugmaker Merck & Co has contributed an HIV medicine for children to an international shared patent pool in a move that should speed the development of cheap pediatric formulations for use in poor countries.

Published
24 February 2015
From
Reuters
amfAR Report Examines Controversial Pricing of Hepatitis C Treatment

The new amfAR report, titled “Hepatitis C and Drug Pricing: The Need for a Better Balance,” urges structural changes that alter the pricing incentives for pharmaceutical companies in such a way that they cannot charge exorbitant prices for their products, however effective they may be.

Published
19 February 2015
From
amfAR
The Drug That Is Bankrupting America

With a rational U.S. drug pricing system, private investors would expect to earn a reasonable multiple of their R&D for a highly successful drug, perhaps even 5 to 10 times the R&D outlays, in order to reflect the long time horizons and high uncertainties surrounding drug development. Yet at a treatment course of $84,000, the multiple for Sovaldi looks to be around 40 times or more.

Published
18 February 2015
From
Huffington Post
Patient groups rank ViiV Healthcare #1 in corporate reputation survey, again

PatientView surveyed 1,150 patient groups from 58 countries and asked them about the corporate reputation of 37 pharma companies. The respondents ranked ViiV Healthcare number one across the board. Gilead fell from the #2 ranking position in 2013 to #14 in 2014—likely a consequence of the controversially high prices for specialty hep C meds.

Published
16 February 2015
From
Bio Pharma Dive
How ViiV Healthcare became a pharma favorite for patient groups

Earlier this week, PatientView published the results of its country survey, which asked more than 1,000 global patient groups to rank biopharmaceutical companies based on their overall "corporate reputation." For the second year in a row, ViiV Healthcare, a joint venture between Pfizer, GlaxoSmithKline, and Shionogi and headquartered in the U.K. (which may also have the biggest IPO for a pharma company ever later this year), emerged as number one.

Published
16 February 2015
From
BioPharma Dive
Healthcare: The race to cure rising drug costs

The controversy over hepatitis C drug prices has highlighted the broader question of whether pharmaceutical companies can defend their premium pricing model in the world’s biggest healthcare market. It is a battle that big pharma risks losing, raising questions over the economic model of an industry that relies heavily on US profits to reward investors and finance new drugs.

Published
13 February 2015
From
Financial Times
← First12345...75Next →

Filter by country